Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 58, Issue 6, 2012, Pages 916-923

  Lock, Richard B ^a   Carol, Hernan ^a   Morton, Christopher L ^b   Keir, Stephen T ^c   Reynolds, C Patrick ^d   Kang, Min H ^d   Maris, John M ^e   Wozniak, Amy W ^b   Gorlick, Richard ^f   Kolb, E Anders ^g   Houghton, Peter J ^h   Smith, Malcolm A ⁱ  

^a Australia   (Australia)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^g NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^h NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; GSK923295A; Preclinical testing

Indexed keywords

ANTINEOPLASTIC AGENT; CENTROMERE PROTEIN E; GSK 923295A; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SCREENING; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RHABDOID TUMOR; RHABDOMYOSARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS, EXPERIMENTAL; SARCOSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863338259     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23176     Document Type: Article

References (34)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Jackson JR, Patrick DR, Dar MM, et al. Targeted anti-mitotic therapies: Can we improve on tubulin agents? Nat Rev Cancer 2007; 7: 107-117.
3. Garuti L, Roberti M, Bottegoni G. Small molecule aurora kinases inhibitors. Curr Med Chem 2009; 16: 1949-1963.
4. Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008; 14: 1639-1648.
5. Vijapurkar U, Wang W, Herbst R. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 2007; 67: 237-245.
6. Haque SA, Hasaka TP, Brooks AD, et al. Monastrol, a prototype anti-cancer drug that inhibits a mitotic kinesin, induces rapid bursts of axonal outgrowth from cultured postmitotic neurons. Cell Motil Cytoskeleton 2004; 58: 10-16.
7. Warner SL, Gray PJ, Von Hoff DD. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol 2006; 33: 436-448.
8. Yen TJ, Compton DA, Wise D, et al. CENP-E, a novel human centromere-associated protein required for progression from metaphase to anaphase. EMBO J 1991; 10: 1245-1254.
9. Schaar BT, Chan GK, Maddox P, et al. CENP-E function at kinetochores is essential for chromosome alignment. J Cell Biol 1997; 139: 1373-1382.
10. Chan GK, Jablonski SA, Sudakin V, et al. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J Cell Biol 1999; 146: 941-954.
11. Mao Y, Desai A, Cleveland DW. Microtubule capture by CENP-E silences BubR1-dependent mitotic checkpoint signaling. J Cell Biol 2005; 170: 873-880.
12. Yao X, Abrieu A, Zheng Y, et al. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat Cell Biol 2000; 2: 484-491.
13. Rieder CL, Maiato H. Stuck in division or passing through: What happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004; 7: 637-651.
14. Tao W. The mitotic checkpoint in cancer therapy. Cell Cycle 2005; 4: 1495-1499.
15. Suijkerbuijk SJ, van Osch MH, Bos FL, et al. Molecular causes for BUBR1 dysfunction in the human cancer predisposition syndrome mosaic variegated aneuploidy. Cancer Res 2010; 70: 4891-4900.
16. Hanks S, Coleman K, Reid S, et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nature Genet 2004; 36: 1159-1161.
17. Weaver BA, Silk AD, Montagna C, et al. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007; 11: 25-36.
18. Wood KW, Lad L, Luo L, et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA 2010; 107: 5839-5844.
19. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
20. Carol H, Lock R, Houghton PJ, et al. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009; 53: 1255-1263.
21. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010; 55: 26-34.
22. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
23. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 37-45.
24. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharm Stat.
25. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988; 48: 4189-4195.
26. Graham C, Tucker C, Creech J, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006; 12: 223-234.
27. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005; 11: 6950-6958.
28. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
29. Plowman JCR, Alley M, Sausville E, et al. US-NCI testing procedures. In: Feibig HH BA, editor. Relevance of tumor models for anticancer drug development. Basel: Karger; 1999. pp. 121-135.
30. Kang M, Smith MA, Morton CL, et al. National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer.
31. Paull KD, Lin CM, Malspeis L, et al. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 1992; 52: 3892-3900.
32. DeBonis S, Skoufias DA, Lebeau L, et al. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther 2004; 3: 1079-1090.
33. Lee CW, Belanger K, Rao SC, et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2008; 26: 249-255.
34. Knox JJ, Gill S, Synold TW, et al. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND 168). Invest New Drugs 2008; 26: 265-272.